GBP · £
USD · $
EUR · €
CAD · C$
AUD · A$
Tirzepatide
Dual GIP/GLP-1 agonist · laboratory research material
A Tirzepatide research vial with clear dual-receptor context, verified contents and strict separation from authorised medicinal products.
Subscribe for updates
This product is coming soon. Leave your email and we will notify you when Tirzepatide is in stock.
You would earn 49 points
- 5mgStrength
- ≥99% HPLCPurity target
- UK dispatchFrom the UK
- CoAOn request
Free UK shipping over £100
900+ reviews · trusted product quality
HPLC purity documentation
Dispatched from the UK
APH Peptides Tirzepatide is listed as a 5mg lyophilised research peptide for laboratory use - coming soon.
At a glance:
- 5mg lyophilised (freeze-dried) vial
- HPLC purity target ≥99%
- Clear vial + box labelling under APH Peptides
- UK dispatch with tracked UK shipping
- CoA / purity documentation available on request
- Strictly for laboratory research - not for human consumption
Compound Tirzepatide Full name Tirzepatide Strength 5mg Form Lyophilised powder Purity target ≥99% (HPLC) Class Dual (GIP/GLP-1) receptor agonist (research) Status Subscribe below for stock notes Use Laboratory research only
In laboratory and preclinical literature, Tirzepatide is studied as a dual (GIP/GLP-1) receptor agonist, used in models examining combined incretin-pathway signalling - a research angle that builds on single-agonist GLP-1 literature by adding GIP receptor activity. APH Peptides supplies material for controlled lab protocols only - not for human use.
Supplied as a 5mg lyophilised vial. Labs reconstitute under sterile technique using solvents approved by their institution. Storage, concentration and experimental design sit with your SOP - APH Science does not provide human dosing guidance.
Free UK shipping on all orders over £100. Peptide orders use the same APH Science warehouse workflow with plain, unbranded outer packaging and cold-chain ready packing where needed.
Research peptide batches target HPLC purity of ≥99%. Certificate of Analysis style documentation will be available for research lots. All APH Peptides products are for laboratory research only and are not intended for human consumption.
Testimonials
Key benefits
Dual Action: GIP + GLP-1
Tirzepatide is studied as a dual (GIP/GLP-1) receptor agonist, a frequently-referenced compound in next-generation incretin and metabolic research literature.
Try now
Appetite Control
The GLP-1 arm is studied for its role in appetite signalling, with research comparing dual-agonist engagement against GLP-1 agonism alone in controlled models.
Try now
Glucose + Weight Research
Incretin activity sits upstream of insulin and weight-management pathways, so Tirzepatide is catalogued for controlled metabolic and body-weight study models.
Try now
Tirzepatide 5mg
Tirzepatide is a dual-agonist research peptide referenced across next-generation incretin literature. A 5mg lyophilised vial with HPLC purity targeting, clear labelling and UK dispatch. Catalogued for controlled laboratory use only.
-
5mg vialLyophilised research peptide, clearly labelled with batch identity.
-
Dual agonistStudied for combined GIP and GLP-1 receptor activity in one compound.
-
Lab-grade supplyHPLC purity targeting and UK dispatch for controlled research use.
Dual action: GIP + GLP-1
Single-agonist compounds engage one incretin receptor. Tirzepatide is studied for activity at two: GIP and GLP-1. Research interest centres on how combined incretin signalling compares with GLP-1 agonism alone in metabolic pathway models.
-
GIP receptorStudied for its role in nutrient signalling alongside the incretin pathway.
-
GLP-1 receptorThe most-cited incretin target in appetite and glucose research.
-
Combined signallingDual engagement is the reference point for next-generation incretin studies.
Appetite control
The GLP-1 arm of Tirzepatide is studied for its role in appetite signalling. Research literature examines how dual-agonist engagement influences hunger pathways and food intake in controlled models, relative to single-agonist compounds.
-
Hunger signallingGLP-1 pathway activity is the most-studied appetite signal in incretin research.
-
Dual-agonist modelStudies compare combined GIP and GLP-1 engagement against GLP-1 alone.
-
Controlled modelsFindings come from controlled study designs, not anecdote.
Glucose support
Incretin receptors sit upstream of insulin signalling, so Tirzepatide is studied for its relationship with glucose regulation. Research interest includes how dual-agonist activity interacts with insulin response and blood-sugar pathways in metabolic models.
-
Insulin responseIncretin signalling is studied for its role in glucose-dependent insulin pathways.
-
Blood-sugar pathwaysGlucose regulation is a core axis of dual-agonist metabolic research.
-
Metabolic modelsCatalogued for laboratory investigation of glucose handling.
Weight control
Appetite signalling plus glucose pathways is why Tirzepatide anchors weight-management research. Literature examines body-weight outcomes in dual-agonist models as a combined question of intake and metabolic handling, studied under controlled conditions.
-
Body-weight modelsWeight outcomes are studied as intake plus metabolic handling, not one lever.
-
Intake sideAppetite signalling is one half of the weight-control research question.
-
Metabolic sideGlucose and incretin pathways make up the other half.
Product FAQs
Contact us Contact usWhat is Tirzepatide?
Tirzepatide is a research peptide studied as a dual (GIP/GLP-1) receptor agonist, used in laboratory and preclinical literature examining combined incretin-pathway signalling.
Is Tirzepatide available now?
Tirzepatide is coming soon. Subscribe on this page and we will email you the moment it is in stock.
What strength will it be supplied at?
5mg lyophilised vial, HPLC purity target ≥99%.
What makes Tirzepatide a 'dual agonist'?
Tirzepatide is catalogued as engaging both GIP and GLP-1 receptors within the same molecule - a broader research angle than single-agonist GLP-1 compounds like Semaglutide.
How does Tirzepatide differ from Semaglutide or Retatrutide?
Semaglutide is studied as a single GLP-1 agonist, Tirzepatide as a dual GIP/GLP-1 agonist, and Retatrutide as a triple GIP/GLP-1/glucagon agonist - each representing a different point in incretin-receptor research literature.
Is Tirzepatide hormonal like an androgen-receptor SARM?
No. Tirzepatide's research framing sits within dual-agonist metabolic pathway literature, not androgen receptor agonism.
What does HPLC ≥99% mean?
HPLC (high-performance liquid chromatography) purity testing targets ≥99% for research peptide batches - a quality benchmark, not a medical claim.
Storage for research material
Keep sealed, cool, and dry away from direct light. Follow any lot-specific note supplied with the order.
What makes APH Peptides different for this compound?
Tirzepatide will ship under the same UK-owned QC culture as the rest of the APH Science range - clear labelling, third-party testing culture, and plain packaging.
Can I get batch / CoA documentation?
Where certificates of analysis or batch documentation are available for a product, APH Science can supply them on request once stock lands. Include your order number and product name when contacting support.
Where do you ship from?
Orders dispatch from the UK with tracked shipping options. Free UK shipping applies on carts over £100.
How will I know when Tirzepatide is back in stock?
Leave your email in the subscribe card on this page - we will notify you as soon as stock lands.
How are orders packed?
Orders go out in plain, unbranded packaging with no external branding. Tracking is provided so you can follow the parcel in transit.
Is every batch third-party tested?
APH Science targets independent lab verification for research batches before release. Certificate or purity paperwork can be requested where available for your lot.
Is this for human consumption?
No. Research compounds, SARMs, and research peptides are sold strictly for laboratory research purposes only. They are not intended for human consumption, medical use, or as food or dietary supplements.
